| Primary |
| Prophylaxis |
16.9% |
| Upper Respiratory Tract Infection |
14.2% |
| Product Used For Unknown Indication |
8.8% |
| Antibiotic Prophylaxis |
8.1% |
| Cataract Operation |
7.4% |
| Drug Use For Unknown Indication |
6.8% |
| Infection Prophylaxis |
4.1% |
| Pain |
4.1% |
| Pneumonia |
4.1% |
| Urinary Tract Infection |
4.1% |
| Bronchitis |
3.4% |
| Anti-infective Therapy |
2.7% |
| Pyrexia |
2.7% |
| Erysipelas |
2.0% |
| Infection |
2.0% |
| Lyme Disease |
2.0% |
| Muscle Relaxant Therapy |
2.0% |
| Nausea |
2.0% |
| Blood Cholesterol Increased |
1.4% |
| Calculus Urinary |
1.4% |
|
| Pruritus |
9.2% |
| Anaphylactic Shock |
7.7% |
| Pharmaceutical Product Complaint |
7.7% |
| Urticaria |
7.7% |
| Diarrhoea |
6.2% |
| Syncope |
6.2% |
| Wheezing |
6.2% |
| Hepatorenal Syndrome |
4.6% |
| Pallor |
4.6% |
| Pyrexia |
4.6% |
| Rash |
4.6% |
| Renal Failure Acute |
4.6% |
| Ulcerative Keratitis |
4.6% |
| Bronchospasm |
3.1% |
| Device Related Infection |
3.1% |
| Dyspnoea |
3.1% |
| Erythema |
3.1% |
| Hypersensitivity |
3.1% |
| Influenza |
3.1% |
| Loss Of Consciousness |
3.1% |
|
| Secondary |
| Product Used For Unknown Indication |
28.7% |
| Bronchitis |
15.4% |
| Drug Use For Unknown Indication |
5.9% |
| Urinary Tract Infection |
5.9% |
| Diabetes Mellitus |
4.4% |
| Bronchopneumonia |
3.7% |
| Hypertension |
3.7% |
| Immunosuppression |
3.7% |
| Adjuvant Therapy |
2.9% |
| Device Related Infection |
2.9% |
| Myocarditis |
2.9% |
| Pain |
2.9% |
| Pyrexia |
2.9% |
| Anxiety |
2.2% |
| Bronchospasm |
2.2% |
| Chronic Obstructive Pulmonary Disease |
2.2% |
| Myasthenia Gravis |
2.2% |
| Type 2 Diabetes Mellitus |
2.2% |
| Agitation |
1.5% |
| Anal Cancer Stage Ii |
1.5% |
|
| Vomiting |
19.4% |
| Intra-uterine Death |
8.3% |
| Neutropenia |
8.3% |
| Bone Marrow Failure |
5.6% |
| Cyanosis |
5.6% |
| Myocardial Infarction |
5.6% |
| Staphylococcal Infection |
5.6% |
| Treatment Failure |
5.6% |
| Twin Pregnancy |
5.6% |
| Acute Respiratory Failure |
2.8% |
| Angle Closure Glaucoma |
2.8% |
| Clostridial Infection |
2.8% |
| Clostridium Difficile Colitis |
2.8% |
| Dermatitis Allergic |
2.8% |
| Drug Ineffective |
2.8% |
| Foetal Growth Restriction |
2.8% |
| Gastric Stenosis |
2.8% |
| Gastrointestinal Disorder |
2.8% |
| Hepatic Enzyme Increased |
2.8% |
| Hypersensitivity |
2.8% |
|
| Concomitant |
| Product Used For Unknown Indication |
48.4% |
| Drug Use For Unknown Indication |
35.6% |
| Type 2 Diabetes Mellitus |
2.8% |
| Pneumonia |
1.6% |
| Hypertension |
1.2% |
| Infection |
1.1% |
| Pyrexia |
1.0% |
| Blood Pressure Decreased |
0.9% |
| Dialysis |
0.8% |
| Hypercholesterolaemia |
0.8% |
| Prophylaxis |
0.8% |
| Renal Transplant |
0.7% |
| Acute Myocardial Infarction |
0.6% |
| Blood Cholesterol Decreased |
0.6% |
| Pain |
0.6% |
| Anaesthesia |
0.5% |
| Benign Prostatic Hyperplasia |
0.5% |
| Coronary Artery Bypass |
0.5% |
| Heart Transplant |
0.5% |
| Multiple Myeloma |
0.5% |
|
| Vomiting |
26.1% |
| Syncope |
8.7% |
| Rhabdomyolysis |
6.5% |
| Hypertension |
4.3% |
| Jaundice Cholestatic |
4.3% |
| Multi-organ Failure |
4.3% |
| Pneumonia |
4.3% |
| Renal Failure |
4.3% |
| Renal Failure Acute |
4.3% |
| Speech Disorder Developmental |
4.3% |
| Unresponsive To Stimuli |
4.3% |
| Ventricular Fibrillation |
4.3% |
| Visual Impairment |
4.3% |
| Anaemia |
2.2% |
| Atrial Septal Defect |
2.2% |
| Cerebral Haemorrhage |
2.2% |
| Completed Suicide |
2.2% |
| Convulsion |
2.2% |
| Eye Haemorrhage |
2.2% |
| Fear |
2.2% |
|
| Interacting |
| Atrial Fibrillation |
25.0% |
| Hypertension |
25.0% |
| Pneumonia |
25.0% |
| Diabetes Mellitus |
8.3% |
| Gout |
8.3% |
| Renal Failure Chronic |
8.3% |
|
| Prothrombin Time Shortened |
100.0% |
|
